430 related articles for article (PubMed ID: 34349500)
1. Dual-Functional Peptide Driven Liposome Codelivery System for Efficient Treatment of Doxorubicin-Resistant Breast Cancer.
Ahmed KS; Liu S; Mao J; Zhang J; Qiu L
Drug Des Devel Ther; 2021; 15():3223-3239. PubMed ID: 34349500
[TBL] [Abstract][Full Text] [Related]
2. Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect.
Ahmed KS; Shan X; Mao J; Qiu L; Chen J
Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1448-1458. PubMed ID: 30889679
[TBL] [Abstract][Full Text] [Related]
3. Liposome-based codelivery of celecoxib and doxorubicin hydrochloride as a synergistic dual-drug delivery system for enhancing the anticancer effect.
Ahmed KS; Changling S; Shan X; Mao J; Qiu L; Chen J
J Liposome Res; 2020 Sep; 30(3):285-296. PubMed ID: 31223044
[TBL] [Abstract][Full Text] [Related]
4. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.
Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X
Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
6. Reversal of P-glycoprotein-mediated multidrug resistance by doxorubicin and quinine co-loaded liposomes in tumor cells.
Shen Q; Qiu L
J Liposome Res; 2017 Dec; 27(4):293-301. PubMed ID: 27581212
[TBL] [Abstract][Full Text] [Related]
7. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
[TBL] [Abstract][Full Text] [Related]
8. Near-infrared triggered co-delivery of doxorubicin and quercetin by using gold nanocages with tetradecanol to maximize anti-tumor effects on MCF-7/ADR cells.
Zhang Z; Xu S; Wang Y; Yu Y; Li F; Zhu H; Shen Y; Huang S; Guo S
J Colloid Interface Sci; 2018 Jan; 509():47-57. PubMed ID: 28881205
[TBL] [Abstract][Full Text] [Related]
9. Overcoming multidrug resistance by intracellular drug release and inhibiting p-glycoprotein efflux in breast cancer.
Mao J; Qiu L; Ge L; Zhou J; Ji Q; Yang Y; Long M; Wang D; Teng L; Chen J
Biomed Pharmacother; 2021 Feb; 134():111108. PubMed ID: 33341670
[TBL] [Abstract][Full Text] [Related]
10. pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer.
Zhang S; Guo N; Wan G; Zhang T; Li C; Wang Y; Wang Y; Liu Y
J Nanobiotechnology; 2019 Oct; 17(1):109. PubMed ID: 31623608
[TBL] [Abstract][Full Text] [Related]
11. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial targeted doxorubicin derivatives delivered by ROS-responsive nanocarriers to breast tumor for overcoming of multidrug resistance.
Zhong XC; Shi MH; Liu HN; Chen JJ; Wang TT; Lin MT; Zhang ZT; Zhou Y; Lu YY; Xu WH; Gao JQ; Xu DH; Han M; Chen YD
Pharm Dev Technol; 2021 Jan; 26(1):21-29. PubMed ID: 33070673
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells.
Haggag Y; Abu Ras B; El-Tanani Y; Tambuwala MM; McCarron P; Isreb M; El-Tanani M
Expert Opin Drug Deliv; 2020 Nov; 17(11):1655-1669. PubMed ID: 32841584
[TBL] [Abstract][Full Text] [Related]
14. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier.
Lu J; Zhao W; Huang Y; Liu H; Marquez R; Gibbs RB; Li J; Venkataramanan R; Xu L; Li S; Li S
Mol Pharm; 2014 Nov; 11(11):4164-78. PubMed ID: 25265550
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
[TBL] [Abstract][Full Text] [Related]
18. Mitochondria-targeted delivery of doxorubicin to enhance antitumor activity with HER-2 peptide-mediated multifunctional pH-sensitive DQAsomes.
Shi M; Zhang J; Li X; Pan S; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X
Int J Nanomedicine; 2018; 13():4209-4226. PubMed ID: 30140154
[TBL] [Abstract][Full Text] [Related]
19. Rational design of multifunctional micelles against doxorubicin-sensitive and doxorubicin-resistant MCF-7 human breast cancer cells.
Hong W; Shi H; Qiao M; Gao X; Yang J; Tian C; Zhang D; Niu S; Liu M
Int J Nanomedicine; 2017; 12():989-1007. PubMed ID: 28243082
[TBL] [Abstract][Full Text] [Related]
20. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies.
Li B; Xu H; Li Z; Yao M; Xie M; Shen H; Shen S; Wang X; Jin Y
Int J Nanomedicine; 2012; 7():187-97. PubMed ID: 22275834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]